The funding will be used to expand client workflows on their platform and expand presence in the US
Bengaluru-based biotech startup Shilps Sciences announced closing a Pre-series A financing round led by AngelList, which also saw participation from some existing investors. The funding will be used to expand client workflows on their platform and expand presence in the US.
“We are excited that the current round of funding enables us to accelerate biology application development on our platform and expand our presence in the US ecosystem. We are also engaging with key opinion leaders and early access partners in this field,” said Ashwin Lal, CEO, Shilps.
“Delighted to see a deep science startup from India developing disruptive technology for the world. Synthetic biology is the next frontier that will fundamentally transform a vast range of industries, “says Abhishek Nag, lead Investor, AngelList India syndicate.
“We are excited to have supported and funded Shilps, a deep science startup, to help realise their vision of developing world leading technologies, while being incubated at C-CAMP,” said Dr Taslimarif Saiyed, CEO and Director, C-CAMP.
The startup was also recognised by Applied Ventures, the venture capital arm of Applied Materials as one of the top 3 deep tech startups in India. As part of Applied Startup Technology & Research Accelerator, they have an MoU for scientific collaboration.
